Bio-Gene Advances Pivotal Flavocide Toxicity Study Toward Regulatory Approval

Bio-Gene Technology Ltd. ( (AU:BGT) ) just unveiled an update.

Bio-Gene Technology has commenced a pivotal extended one-generation reproductive toxicity study in rats for its novel insecticidal active ingredient, Flavocide, a core requirement for regulatory approval in Australia and other key jurisdictions. The study, conducted under OECD 443 guidelines and Good Laboratory Practice, will generate essential reproductive, developmental and systemic toxicity data to support Flavocide’s registration with the Australian Pesticides & Veterinary Medicines Authority and underpin its broader commercialisation strategy.

A completed dose range-finding phase has established dosing for the main study, whose in-life phase is expected to conclude in July 2026, with preliminary results due in September and final reporting in November 2026. As an internationally recognised and mutually accepted test, the OECD 443 study is expected to strengthen Bio-Gene’s mammalian toxicology dossier, marking a significant milestone that could enhance regulatory confidence, facilitate international submissions and advance the company’s position in the global insecticide market.

The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.

More about Bio-Gene Technology Ltd.

Bio-Gene Technology Ltd. is an Australian biotechnology company focused on developing novel insecticides derived from natural sources. Its lead active ingredient, Flavocide, is being advanced for use in products targeting insect pests, with regulatory registration sought in Australia and other international markets.

Average Trading Volume: 194,837

Technical Sentiment Signal: Buy

Current Market Cap: A$10.07M

Learn more about BGT stock on TipRanks’ Stock Analysis page.